+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia Pacific Cell Line Development Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Product, Application

  • ID: 5006325
  • Report
  • March 2021
  • Region: Asia Pacific
  • 113 Pages
  • The Insight Partners
UP TO OFF until Jun 30th 2022

FEATURED COMPANIES

  • Corning Incorporated
  • General Electric
  • Lonza
  • Merck KGaA
  • SELEXIS
  • WuXi AppTec
The Asia Pacific cell line development market is expected to reach US$ 2,828.53million in 2027 from US$ 993.09million in 2019. The market is estimated to grow with a CAGR of 14.1% from 2020-2027.





The market growth is primarily driven by the increasing government participation in the cell line development projects and an upsurge in the development of the biotechnology industry. However, the susceptibility of cell lines toward contamination by various microorganisms hinders the market growth.

The Chinese government recognizes the country's potential in sustainable development, leading to leadership in the global biotechnology industry; therefore, it offers financial and regulatory assistance to predominantly support the research, development, and innovation strategies adopted by various companies. China has ~35 stem cell clinic research programs registered with the National Health Commission and the National Medical Products Administration. Along with various strategic industrial planning, the Chinese government is targeted development in recent years, particularly within the domestic biomedical sector, through strategic planning and research funding. In 2018, the Ministry of Science and Technology released the 2019 Annual Project Application Guide for Stem Cell and Transformation Research project. The government projected financing US$ 58 million (400 million Yuan) to support stem cell research. Two of the 22 nationally funded stem cell clinical research projects are correlated to c-kit cells.

Further, the government of South Korea has invested a substantial amount in the launch of various projects. According to an article published in Business Korea in August 2018, the government ministries - including the Ministry of Health and Welfare (MOHW); Ministry of Science and ICT (MSIT); and Ministry of Trade, Industry, and Energy (MOTIE) - were looking forward to launching a project named as National New Drug Development Support Project. It has invested ~US$ 1.78 billion (KRW 2 trillion) in this project. Hence, such high government investments drive the cell line development market growth in Asia Pacific countries.

The COVID-19 pandemic, leading to uncertainties around economic recovery, has affected the growth of the pharmaceutical industry in Asia Pacific. Cell lines are widely used in the development of various pharmaceuticals and biologics, as well as in applications such as drug screening, cell-based assay development, functional gene studies, diagnostics, and tissue engineering. Cell line development is crucial for examining the efficiency and toxicity of drugs in vitro. It reduces time, effort and cost, and minimizes the chance of drug failure in the clinical trial stage that involves the production of recombinant proteins such as monoclonal antibodies, growth factors, enzymes, and the novel approach of developing immunotherapy to treat cancer using a wide variety of expression systems. In the last few years, the collaboration between cell line developers or manufacturers and novel therapeutics companies has boosted the expansion of the cell-line development market. However, the pandemic has gathered the major attention toward the drug and vaccine development against the novel coronavirus, leading to the temporary suspension of other research activities.

On the basis of type, the North America cell line development market is segmented into primary cell lines, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell line segments held the largest market share in 2019, whereas the hybridomas segment is anticipated to register the highest CAGR in the market during the forecast period. The North America cell line development market, by product, is segmented into equipment, and media and reagents. The media & reagent segment held a larger share of the market in 2019, and it is anticipated to register a higher CAGR in the market from 2020 to 2027. Based on application, the North America cell line development market is segmented into drug discovery, bioproduction, and tissue engineering. The bioproduction segment held the largest market share in 2019. However, the drug discovery segment is anticipated to register the highest CAGR in the market during 2020-2027.

The Chinese Academy of Sciences (CAS) and National Stem Cell Foundation of Australia (NSCFA) are among the primary and secondary sources referred to while preparing the report on the Asia Pacific cell line development market.
Frequently Asked Questions about the Asian Pacific Cell Line Development Market

What is the estimated value of the Asian Pacific Cell Line Development Market?

The Asian Pacific Cell Line Development Market was estimated to be valued at $993.1 Million in 2019.

What is the growth rate of the Asian Pacific Cell Line Development Market?

The growth rate of the Asian Pacific Cell Line Development Market is 14.1%, with an estimated value of $2828.5 Million by 2027.

What is the forecasted size of the Asian Pacific Cell Line Development Market?

The Asian Pacific Cell Line Development Market is estimated to be worth $2828.5 Million by 2027.

Who are the key companies in the Asian Pacific Cell Line Development Market?

Key companies in the Asian Pacific Cell Line Development Market include Merck KGaA, Thermo Fisher Scientific, Inc., SELEXIS, WuXi AppTec, General Electric and Corning Incorporated.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Corning Incorporated
  • General Electric
  • Lonza
  • Merck KGaA
  • SELEXIS
  • WuXi AppTec

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Cell line development Market - By Type
1.3.2 Cell line development Market - By Product
1.3.3 Cell line development Market - By Application
1.3.4 Asia PacificCell line development Market - By Country
2. Asia Pacific Cell Line Development Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia PacificCell Line Development Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Cell Line Development Market- Asia Pacific PEST Analysis
4.3 Expert Opinion
5. Asia PacificCell Line Development Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 High Growth in Investments from the Government in Development of Cell Line
5.1.2 Rising Development of the Biotechnology Sector
5.2 Market Restraints
5.2.1 Multiple Challenges in Cell Line Development
5.3 Market Opportunity
5.3.1 Increasing Stem Cell Research Regarding Cell Line Development Market
5.4 Future Trend
5.4.1 GrowingCompany Participation in the Cell Line Development Market
5.5 Impact Analysis
6. Cell Line Development Market - Asia Pacific Analysis
6.1 Asia PacificCell Line Development Market Revenue Forecasts and Analysis
7. Asia PacificCell Line Development Market Analysis and Forecasts To 2027 - ByType
7.1 Overview
7.2 Cell Line Development Market, by Type, 2019& 2027 (% Share)
7.3 Primary Cell Line
7.3.1 Overview
7.3.2 Primary Cell Line Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Hybridomas
7.4.1 Overview
7.4.2 Hybridomas Market Revenue and Forecast to 2027 (US$ Mn)
7.5 Continuous Cell Lines
7.5.1 Overview
7.5.2 Continuous Cell Lines Market Revenue and Forecast to 2027 (US$ Mn)
7.6 Recombinant Cell Line
7.6.1 Overview
7.6.2 Recombinant Cell Line Market Revenue and Forecast to 2027 (US$ Mn)
8. Asia Pacific Cell Line Development Market Analysis and Forecasts To 2027 - ByProduct
8.1 Overview
8.2 Cell Line Development Market, by Product, 2019& 2027 (% Share)
8.3 Equipment
8.3.1 Overview
8.3.2 Equipment Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Media and Reagent
8.4.1 Overview
8.4.2 Media and Reagent Market Revenue and Forecast to 2027 (US$ Mn)
9. Asia PacificCell Line Development Market Analysis - ByApplication
9.1 Overview
9.2 Cell Line Development Market Share by Application 2019& 2027 (%)
9.3 Drug Discovery
9.3.1 Overview
9.3.2 Drug Discovery Market Revenue and Forecast to 2027 (US$ Mn)
9.4 Bioproduction
9.4.1 Overview
9.4.2 Bioproduction Market Revenue and Forecast to 2027 (US$ Mn)
9.5 Tissue Engineering
9.5.1 Overview
9.5.2 Tissue Engineering Market Revenue and Forecast to 2027 (US$ Mn)
10. Cell Line Development Market Revenue and Forecasts To 2027 - Geographical Analysis
10.1 Asia Pacific Cell Line Development Market, Revenue and Forecast to 2027
10.1.1 Overview
10.1.2 Asia Pacific Cell Line Development Market, Revenue and Forecast to 2027 (US$ Mn)
10.1.3 Asia Pacific Cell Line Development Market, Revenue and Forecast to 2027, By Type (US$ Mn)
10.1.4 Asia Pacific Cell Line Development Market, Revenue and Forecast to 2027, By Product (US$ Mn)
10.1.5 Asia Pacific Cell Line Development Market, Revenue and Forecast to 2027, By Application (US$ Mn)
10.1.6 Asia Pacific Cell Line Development Market, Revenue and Forecast to 2027, By Country (%)
10.1.7 China
10.1.7.1 China Cell Line Development Market, Revenue and Forecast to 2027 (US$ Mn)
10.1.7.2 China Cell Line Development Market, Revenue and Forecast to 2027, By Type (US$ Mn)
10.1.7.3 China Cell Line Development Market, Revenue and Forecast to 2027, By Product (US$ Mn)
10.1.7.4 China Cell Line Development Market, Revenue and Forecast to 2027, By Application (US$ Mn)
10.1.8 Japan
10.1.8.1 Japan Cell Line Development Market, Revenue and Forecast to 2027 (US$ Mn)
10.1.8.2 Japan Cell Line Development Market, Revenue and Forecast to 2027, By Type (US$ Mn)
10.1.8.3 Japan Cell Line Development Market, Revenue and Forecast to 2027, By Product (US$ Mn)
10.1.8.4 Japan Cell Line Development Market, Revenue and Forecast to 2027, By Application (US$ Mn)
10.1.9 India
10.1.9.1 India Cell Line Development Market, Revenue and Forecast to 2027 (US$ Mn)
10.1.9.2 India Cell Line Development Market, Revenue and Forecast to 2027, By Type (US$ Mn)
10.1.9.3 India Cell Line Development Market, Revenue and Forecast to 2027, By Product (US$ Mn)
10.1.9.4 India Cell Line Development Market, Revenue and Forecast to 2027, By Application (US$ Mn)
10.1.10 South Korea
10.1.10.1 South Korea Cell Line Development Market, Revenue and Forecast to 2027 (US$ Mn)
10.1.10.2 South Korea Cell Line Development Market, Revenue and Forecast to 2027, By Type (US$ Mn)
10.1.10.3 South Korea Cell Line Development Market, Revenue and Forecast to 2027, By Product (US$ Mn)
10.1.10.4 South Korea Cell Line Development Market, Revenue and Forecast to 2027, By Application (US$ Mn)
10.1.11 Australia
10.1.11.1 Australia Cell Line Development Market, Revenue and Forecast to 2027 (US$ Mn)
10.1.11.2 Australia Cell Line Development Market, Revenue and Forecast to 2027, By Type (US$ Mn)
10.1.11.3 Australia Cell Line Development Market, Revenue and Forecast to 2027, By Product (US$ Mn)
10.1.11.4 Australia Cell Line Development Market, Revenue and Forecast to 2027, By Application (US$ Mn)
11. Impact of COVID-19 Pandemic on Asia PacificCell Line Development Market
11.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic
12. Company Profiles
12.1 Merck KGaA
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Financial Overview
12.1.4 Product Portfolio
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Thermo Fisher Scientific, Inc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Financial Information
12.2.4 Product /Services Portfolio
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 SELEXIS
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Financial Overview
12.3.4 Product/Service Portfolio
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 WuXiAppTec
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Financial Overview
12.4.4 Service Portfolio
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 General Electric
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Financial Overview
12.5.4 Product Portfolio
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Lonza
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Financial Information
12.6.4 Product Portfolio
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Corning Incorporated
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Financial Overview
12.7.4 Product Portfolio
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. Appendix
13.1 About the Publishers
13.2 Glossary of terms
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • SELEXIS
  • WuXi AppTec
  • General Electric
  • Lonza
  • Corning Incorporated
Note: Product cover images may vary from those shown